BioMarin Pharmaceutical Inc., of Novato, Calif., said updated data from its Phase I/II extension study of GALNS (N-acetylgalactosamine 6-sulfatase), showed no new or consistent patterns of clinically meaningful or treatment-limiting adverse events in patients with mucopolysaccharidosis Type IVA.